Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06069440
Other study ID # DINOGMI-2023
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 1, 2022
Est. completion date August 1, 2023

Study information

Verified date October 2023
Source Universita degli Studi di Genova
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

During a submaximal task, gradual muscle fatigue occurs, which inevitably results in a decline in performance (mechanical failure). Elite athletes are known to employ unconscious compensatory strategies during fatiguing submaximal tasks in an attempt to delay the onset of mechanical failure as long as possible. The purpose of this study was to gain valuable insight into the strategies used by elite swimmers to cope with mechanical failure. Twenty-two swimmers were subjected to a swim test consisting of swimming as long as possible at a predetermined and controlled pace. A light strip positioned at the bottom of the pool allows athletes to get feedback on which gait to keep. The kinematics (stroke rate, stroke length, and efficiency index) and electrical activity of 10 muscle groups were analyzed and compared at the beginning of the test (non-fatiguing conditions), just before the athlete lost the ability to maintain the predetermined pace (pre-mechanical failure), and after the athlete lost the ability to maintain the pace (mechanical failure). It is hypothesized that as fatigue becomes more pronounced and the point of inability to maintain a predetermined speed is approached, increased EMG activity will occur in key muscles while other muscle groups may show more obvious signs of fatigue. In addition, changes in the rhythm and coordination of upper limb movements may occur.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date August 1, 2023
Est. primary completion date March 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years to 24 Years
Eligibility Inclusion Criteria: 1. Middle- or long-distance swimmer specializing in front crawl 2. At least 3 years of experience in international competition 3. Daily use of flashing light for pace control in aerobic, anaerobic threshold and maximum oxygen consumption training. Exclusion Criteria: 1) Presence of muscle pain or soreness that could prevent the athlete from performing at their best

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Swimming Fatigue Task
Swim freestyle at a steady, controlled pace until mechanical failure (i.e., inability to maintain the predetermined speed) is reached.

Locations

Country Name City State
Italy Università degli Studi di Genova Genova

Sponsors (1)

Lead Sponsor Collaborator
Universita degli Studi di Genova

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Flexor Carpi Radialis muscle activity Electromyographic signal analysis (Root Mean Square) up to 10 minutes
Primary Biceps Brachii muscle activity Electromyographic signal analysis (Root Mean Square) up to 10 minutes
Primary Triceps Brachii caput lateralis muscle activity Electromyographic signal analysis (Root Mean Square) up to 10 minutes
Primary Deltoideus Lateralis muscle activity Electromyographic signal analysis (Root Mean Square) up to 10 minutes
Primary Latissimus Dorsi muscle activity Electromyographic signal analysis (Root Mean Square) up to 10 minutes
Primary Superior Trapezius muscle activity Electromyographic signal analysis (Root Mean Square) up to 10 minutes
Primary Erector Spinae muscle activity Electromyographic signal analysis (Root Mean Square) up to 10 minutes
Primary Pectoralis Major pars clavicularis muscle activity Electromyographic signal analysis (Root Mean Square) up to 10 minutes
Primary Rectus Femoris muscle activity Electromyographic signal analysis (Root Mean Square) up to 10 minutes
Primary Biceps Femoris muscle activity Electromyographic signal analysis (Root Mean Square) up to 10 minutes
Primary Kinematic parameters stroke frequency (time required to complete a stroke cycle) up to 10 minutes
Primary Kinematic parameters stroke length (distance traveled during each stroke cycle)) up to 10 minutes
Secondary Flexor Carpi Radialis muscle fatigue time-course evolution of the median frequency of the power density spectrum (MF [Hz]) of the sEMG signal up to 10 minutes
Secondary Biceps Brachii muscle fatigue time-course evolution of the median frequency of the power density spectrum (MF [Hz]) of the sEMG signal up to 10 minutes
Secondary Triceps Brachii caput lateralis muscle fatigue time-course evolution of the median frequency of the power density spectrum (MF [Hz]) of the sEMG signal up to 10 minutes
Secondary Deltoideus Lateralis muscle fatigue time-course evolution of the median frequency of the power density spectrum (MF [Hz]) of the sEMG signal up to 10 minutes
Secondary Latissimus Dorsi muscle fatigue time-course evolution of the median frequency of the power density spectrum (MF [Hz]) of the sEMG signal up to 10 minutes
Secondary Superior Trapezius muscle fatigue time-course evolution of the median frequency of the power density spectrum (MF [Hz]) of the sEMG signal up to 10 minutes
Secondary Erector Spinae muscle fatigue time-course evolution of the median frequency of the power density spectrum (MF [Hz]) of the sEMG signal up to 10 minutes
Secondary Pectoralis Major pars clavicularis muscle fatigue time-course evolution of the median frequency of the power density spectrum (MF [Hz]) of the sEMG signal up to 10 minutes
Secondary Rectus Femoris muscle fatigue time-course evolution of the median frequency of the power density spectrum (MF [Hz]) of the sEMG signal up to 10 minutes
Secondary Biceps Femoris muscle fatigue time-course evolution of the median frequency of the power density spectrum (MF [Hz]) of the sEMG signal up to 10 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1